Cargando…
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20–30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896178/ https://www.ncbi.nlm.nih.gov/pubmed/35239451 http://dx.doi.org/10.1080/19420862.2022.2044435 |